Cost–utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand

OBJECTIVES: This study aimed to analyse the cost–utility and budget impact of adding tocilizumab to the standard treatment for patients with refractory systemic juvenile idiopathic arthritis (sJIA) in Thailand. DESIGN: Economic evaluation using a decision-analytical model. SETTING: Thailand. PARTICI...

Descripción completa

Detalles Bibliográficos
Autores principales: Kittiratchakool, Nitichen, Kulpokin, Disorn, Chanjam, Chonticha, Vilaiyuk, Soamarat, Charuvanij, Sirirat, Phongsamart, Gun, Khaosut, Parichat, Tanya, Manasita, Nanagara, Ratanavadee, Nantapaisarn, Sira, Leelahavarong, Pattara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493110/
https://www.ncbi.nlm.nih.gov/pubmed/32933962
http://dx.doi.org/10.1136/bmjopen-2020-037588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493110/
https://www.ncbi.nlm.nih.gov/pubmed/32933962
http://dx.doi.org/10.1136/bmjopen-2020-037588

Ejemplares similares